Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Mol Cancer Res. 2020 Feb 25;18(6):873–882. doi: 10.1158/1541-7786.MCR-19-0661

Fig. 4: No observable toxicity after pHLIP-αKu80(γ) treatment.

Fig. 4:

(A) Body weights of control and pHLIP-αKu80(γ)-treated nude (left) and BALBc/Rw (right) (nude mice: two-way RM ANOVA, effect of treatment P = 0.60, n = 3 mice/group; BALBc/Rw mice: two-way RM ANOVA, effect of treatment, P = 0.88, n = 8 mice/group). (B) Serum chemistry analysis in control and pHLIP-αKu80(γ)-treated mice (unpaired t-tests, creatinine: P = 0.12, urea nitrogen: P = 0.45, AST: P = 0.31, ALT: P = 0.25, n = 3 mice/group). (C) Peripheral blood cell analysis in control and pHLIP-αKu80(γ)-treated mice (1-way ANOVA, white blood cells P = 0.74, red blood cells: P = 0.40, platelets: P = 0.75, n = 3 mice/group). (D) Bone marrow cellularity in control and pHLIP-αKu80(γ)-treated mice (unpaired t-test, P = 0.64, n = 3 mice/group). (E) Serum cytokine levels in mice treated with vehicle, pHLIP-αKu80(γ) (5 mg/kg), or lipopolysaccharide (LPS, 10 mg/kg) (two-way ANOVA, effect of treatment P < 0.0001; Tukey’s multiple comparisons test, vehicle vs. pHLIP-αKu80(γ): P = 0.88. vehicle vs. LPS: P < 0.0001; n = 3 mice/group). Data are represented as mean±SEM.